港股異動 | 歌禮制藥-B(1672.HK)漲超4% FXR激動劑ASC42在美國I期臨牀試驗中取得良好數據
格隆匯6月17日丨歌禮制藥-B(1672.HK)現報3.47港元,漲4.2%,最新市值38億港元。歌禮制藥昨日晚間發公告稱,公司全資附屬公司甘萊製藥有限公司("甘萊")的非酒精性脂肪性肝炎(NASH)候選藥物法尼醇X受體(FXR)激動劑ASC42在美國I期臨牀試驗中取得良好的安全性和藥效學生物標誌物頂線數據。ASC42是一款由甘萊完全自主研發、有望成爲同類最佳的新型高效選擇性非甾類FXR激動劑。ASC42既可作爲單藥使用,也可與甲狀腺激素β受體(THR-β)激動劑ASC41或脂肪酸合成酶(FASN)抑制劑ASC40聯合使用。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.